췌장암 치료제 시장 : 유형, 제품, 최종 사용자별 - 세계 예측(2025-2030년)

The Pancreatic Cancer Therapeutics Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 9.95%, to USD 9.09 billion by 2030.

The pancreatic cancer therapeutics market is a critical segment of the oncology sector, focused on developing treatments that target malignant cells in the pancreas. The scope of this market extends to targeted therapies, chemotherapy, radiation therapy, and emerging options such as immunotherapy and gene therapy. This market's growth is driven by the rising prevalence of pancreatic cancer, an aging population, increased awareness, and advancements in medical research. The necessity of these therapeutics stems from the historically low survival rate associated with pancreatic cancer and the urgent need for innovative treatments that improve patient outcomes. Major end-users include hospitals, cancer research centers, and pharmaceutical companies involved in R&D.

Key growth factors influencing the market include technological advances in diagnostic procedures, a robust pipeline of drugs, increasing investments in R&D, and government initiatives supporting cancer research. Additionally, collaborations between biotechnology firms and research institutions are creating potential opportunities, especially in personalized medicine and biomarker discovery. Recommendations to capitalize on these opportunities involve strategic partnerships, focusing on niche segments such as precision medicine, and accelerating clinical trials for promising therapies.

However, the market faces limitations such as high treatment costs, stringent regulatory approvals, and challenges in early diagnosis, which impact patient access to therapies. Competitive rivalry and significant time investments in drug development pose further hurdles. Firms can drive innovation by concentrating research efforts on developing less invasive treatments, improving drug delivery systems, and exploring novel combination therapies. Moreover, leveraging AI and big data analytics to enhance drug discovery efficiency is promising.

In conclusion, while the pancreatic cancer therapeutics market offers substantial opportunities for growth through technological advancements and collaborative efforts, addressing cost barriers and regulatory challenges will be crucial. Innovation in treatment modalities and data-driven approaches will pave the way for significant breakthroughs, facilitating business growth and improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pancreatic Cancer Therapeutics Market

The Pancreatic Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of pancreatic cancer cases across the world
  • Government initiatives to expand access to pancreatic cancer treatment options
• Market Restraints
  • Adverse drug recalls and difficulty in availing reimbursement options
• Market Opportunities
  • Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
  • Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
• Market Challenges
  • Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Pancreatic Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pancreatic Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pancreatic Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pancreatic Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pancreatic Cancer Therapeutics Market

A detailed market share analysis in the Pancreatic Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pancreatic Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pancreatic Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer.
• Based on Product, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
• Based on End-Use, market is studied across Cancer Centers/Clinics, Hospitals, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
    • 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
    • 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
  • 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
  • 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pancreatic Cancer Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Endocrine Pancreatic Cancer
• 6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

• 7.1. Introduction
• 7.2. Chemotherapy
• 7.3. Gene Therapy
• 7.4. Immunotherapy
• 7.5. Radiation Therapy
• 7.6. Surgery
• 7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

• 8.1. Introduction
• 8.2. Cancer Centers/Clinics
• 8.3. Hospitals
• 8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
  • 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
  • 12.3.3. PanCAN Announces New & Advanced Research Investment
  • 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
  • 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
  • 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
  • 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
  • 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
  • 12.3.9. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
  • 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
  • 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
  • 12.3.12. Leap Therapeutics Acquires Flame Biosciences
  • 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
  • 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
  • 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

Companies Mentioned

• 1. Abbvie Inc.
• 2. Amgen Inc.
• 3. Ascentage Pharma Group
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bristol-Myers Squibb Company
• 7. C.H. Boehringer Sohn AG & Co. KG
• 8. Carl Zeiss AG
• 9. Carrick Therapeutics Limited
• 10. Cipla Limited
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Eli Lilly and Company
• 13. F. Hoffmann-La Roche AG
• 14. Faeth Therapeutics, Inc.
• 15. FUJIFILM Holdings Corporation
• 16. GE HealthCare Technologies, Inc.
• 17. GenesisCare
• 18. GlaxoSmithKline PLC
• 19. Hetero Healthcare Limited
• 20. ImmunityBio, Inc.
• 21. Innovent Biologics Inc.
• 22. Johnson & Johnson Services, Inc.
• 23. Lupin Limited
• 24. Merck & Co., Inc.
• 25. Mitsubishi Heavy Industries, Ltd.
• 26. NGM Biopharmaceuticals, Inc.
• 27. NovalGen
• 28. Novartis AG
• 29. PanTher Therapeutics, Inc.
• 30. Pfizer, Inc.
• 31. RenovoRx, Inc.
• 32. Sun Pharmaceutical Industries Ltd.
• 33. Teva Pharmaceutical Industries Ltd.
• 34. Zentalis Pharmaceuticals, Inc.